Monthly injection developed for HIV patients to keep AIDS at bay


New Delhi: Good news for HIV patients as a monthly injection is as effective as the daily cocktail of ART medication that they have to currently take.

The long lasing injection can control the killer virus and keep AIDS at bay and experts claim replacing the daily regimen of three or more antiretroviral (ART) pills with a jab will improve compliance.

The Phase III trial, conducted for over a year, was the final hurdle faced before treatments can be licensed.

The tests were carried out by an Irish drug firm and involved HIV patients from 13 countries.

The injection, which has to be administered by a nurse or doctors at present – contains two ART drugs, cabotegravir and rilpirivine.

The new ATLAS trial was a Phase III, the final testing hurdle before a new drug or treatment can be licensed for use on humans.

The study saw nearly 620 patients from 13 countries who had suppressed HIV be given a three-pill standard treatment, before switching to the monthly jab.

ViiV Healthcare, the pharmaceutical firm behind the trial, has now claimed that the injection met its primary goal of long-term viral suppression.

Effectiveness at keeping HIV suppressed was similar between the jab and the three-pill-a-day treatment over a period of 48 weeks.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.